Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
==== Fibrous astrocytes ==== The fibrous astrocytes are usually located within white matter, have relatively few organelles, and exhibit long unbranched cellular processes. This type often has astrocyte endfeet processes that physically connect the cells to the outside of capillary walls when they are in proximity to them.
During Bello's tenure at NFLP, the business grew from $30 million in retail sales, sponsorships and publishing to $3 billion when he left in 1993. Bello is broadly credited with creating the model by which every major sports league now operates. He was ranked 46th on Sporting News' list of Most Powerful People in Sports in 1992. Bello left NFLP on Labor Day in 1993 amid controversy. He resigned as a result of losing a power struggle with then-NFL Commissioner Paul Tagliabue who was seeking to consolidate league operations, including the previously independent NFL Properties under the commissioner's office.
forces had invaded in October during the coup. Activist Barbara Trent disputed this finding, saying in a 1992 Academy Award-winning documentary The Panama Deception that the Panamanian surveys were completed in wealthy, English-speaking neighborhoods in Panama City, among Panamanians most likely to support U.S. actions. Human Rights Watch described the reaction of the civilian population to the invasion as "generally sympathetic".
== External links == United States FDA links to actions United States NIH Factsheet regarding weight loss and athletic performance Dietary Supplements: Balancing Consumer Choice and Safety. A report of the New York State Task Force on Life & the Law. The history of Ephedra (ma-huang).
Sources: en.wikipedia.org
1993/169) Combined Probation Areas (Kent) Order 1993 (S.I. 1993/173) Insurance Companies (Amendment) Regulations 1993 (S.I. 1993/174) Council Tax (Transitional Reduction Scheme) (England) Regulations 1993 (S.I. 1993/175) Motor Vehicles (Wearing of Seat Belts) Regulations 1993 (S.I. 1993/176) Loch Crinan Scallops Fishery Order 1993 (S.I. 1993/177) Local Government Act 1988 (Defined Activities) (Specified Periods) (Scotland) Amendment Regulations 1993 (S.I. 1993/178) Air Navigation (Dangerous Goods) (Fourth Amendment) Regulations 1992 S.I. 1993/179) City of London (Non-Domestic Rating Multiplier) Order 1993 (S.I. 1993/180) Sea Fish Licensing (Variation) Order 1993 (S.I. 1993/188) Spring Traps Approval (Variation) Order 1993 (S.I. 1993/189) New Severn Bridge (Restriction of Navigation) Regulations 1993 (S.I. 1993/190) Council Tax and Non-Domestic Rating (Demand Notices) (England) Regulations 1993 (S.I. 1993/191) Value Added Tax Act 1983 (Interest on Overpayments etc.) (Prescribed Rate) Order 1993 (S.I. 1993/192) Copyright (Certification of Licensing Scheme for Educational Recording of Broadcasts and Cable Programmes) (Educational Recording Agency Limited) (Amendment) Order 1993 (S.I. 1993/193) Local Government Finance Act 1992 (Commencement No. 7 and Amendment) Order 1993 (S.I. 1993/194) Council Tax (Reductions for Disabilities) (Amendment) Regulations 1993 (S.I. 1993/195) Council Tax (Administration and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/196) Friendly Societies Act 1992 (Commencement No. 4) Order 1993 (S.I.
=== Treating vitamin deficiency in newborns === Vitamin K1 is given as an injection to newborns to prevent vitamin K deficiency bleeding. The blood clotting factors of newborn babies are roughly 30–60% that of adult values; this appears to be a consequence of poor transfer of the vitamin across the placenta, and thus low fetal plasma vitamin K. Occurrence of vitamin K deficiency bleeding in the first week of the infant's life is estimated at between 1 in 60 and 1 in 250. Human milk contains 0.85–9.2 μg/L (median 2.5 μg/L) of vitamin K1, while infant formula is formulated in range of 24–175 μg/L. Late onset bleeding, with onset 2 to 12 weeks after birth, can be a consequence of exclusive breastfeeding, especially if there was no preventive treatment. Late onset prevalence reported at 35 cases per 100,000 live births in infants who had not received prophylaxis at or shortly after birth. Vitamin K deficiency bleeding occurs more frequently in the Asian population compared to the Caucasian population. Bleeding in infants due to vitamin K deficiency can be severe, leading to hospitalization, brain damage, and death. Intramuscular injection, typically given shortly after birth, is more effective in preventing vitamin K deficiency bleeding than oral administration, which calls for weekly dosing up to three months of age.
In 2001, the Raleigh Memorial Auditorium complex was expanded with the addition of the Progress Energy Center for the Performing Arts, Meymandi Concert Hall, Fletcher Opera Theater, Kennedy Theatre, Betty Ray McCain Gallery and Lichtin Plaza. Fayetteville Street reopened to vehicular traffic in 2006. A variety of downtown building projects began around this time including the 34-story RBC Bank Tower, multiple condominium projects and several new restaurants. Additional skyscrapers are in the proposal/planning phase. The Carolina Hurricanes won the Stanley Cup the same year, which was North Carolina's first professional sports championship. With the opening of parts of I-540 from 2005 to 2007, a new 70 mi (110 km) loop around Wake County, traffic congestion eased somewhat in the North Raleigh area. Completion of the entire loop is expected to take another 15 years. In 2008, the city's Fayetteville Street Historic District joined the National Register of Historic Places. In September 2010, Raleigh hosted the inaugural Hopscotch Music Festival. Raleigh hosted the 2011 National Hockey League All-Star Game. In April 2011, a devastating EF-3 tornado hit Raleigh, and many other tornadoes touched down in the state (ultimately the largest, but not the strongest outbreak to ever hit the state), killing 24 people. The tornado tracked northeast through parts of downtown, East Central Raleigh and Northeast Raleigh and produced $115 million in damages in Wake County. There were 4 fatalities in the city.
Sources: en.wikipedia.org
copper toxicity / zinc deficiency pregnancy oral contraceptive pill use lymphoma acute and chronic inflammation (it is an acute-phase reactant) rheumatoid arthritis Angina Alzheimer's disease Schizophrenia Obsessive-compulsive disorder
Some bird species undertake shorter migrations, travelling only as far as is required to avoid bad weather or obtain food. Irruptive species such as the boreal finches are one such group and can commonly be found at a location in one year and absent the next. This type of migration is normally associated with food availability. Species may also travel shorter distances over part of their range, with individuals from higher latitudes travelling into the existing range of conspecifics; others undertake partial migrations, where only a fraction of the population, usually females and subdominant males, migrates. Partial migration can form a large percentage of the migration behaviour of birds in some regions; in Australia, surveys found that 44% of non-passerine birds and 32% of passerines were partially migratory. Altitudinal migration is a form of short-distance migration in which birds spend the breeding season at higher altitudes and move to lower ones during suboptimal conditions. It is most often triggered by temperature changes and usually occurs when the normal territories also become inhospitable due to lack of food. Some species may also be nomadic, holding no fixed territory and moving according to weather and food availability. Parrots as a family are overwhelmingly neither migratory nor sedentary but considered to either be dispersive, irruptive, nomadic or undertake small and irregular migrations.
Draculin (named after Count Dracula) is a glycoprotein found in the saliva of vampire bats, Desmodus rotundus. It is a member of the lactotransferrin protein family. It is a single-chain polypeptide protein composed of 708 amino acids, weighing about 88.5 kDa when reduced and 83 kDa when non-reduced, and selectively inhibits FIXa and FXa. It functions as an anticoagulant, inhibiting coagulation factors IX (IXa) and X (Xa) by establishing rapid equilibrium with factor Xa, and is the first natural polypeptide which has been described to show immediate anti-IXa and anti-Xa properties. The rapid equilibrium achieved at comparable concentrations of FXa and Draculin, as well as the lack of any detectable lag phases in assays, supports the conclusion that Draculin is a tight-binding inhibitor. In addition, Draculin inhibits the conversion of prothrombin to thrombin, preventing fibrinogen from converting to fibrin. These two processes inhibit blood coagulation thus keeping the blood of the bitten victim from clotting while the bat is drinking. The activation of factor X is a common point between the intrinsic and extrinsic pathway of blood coagulation.
=== Length === Most classical cannabinoids are 21-carbon compounds, but variations in the side-chain length attached to the aromatic ring exist. In THC, CBD, and CBN, the side-chain is a pentyl (5-carbon) chain. Propyl (3-carbon) chain variants are named with the suffix varin (THCV, CBDV, CBNV), while heptyl (7-carbon) chain variants are named phorol (THCP, CBDP).
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.